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There are a multitude of nuclear receptor coactivators, and as a result, individual constituents of activation 
complexes are often overlooked when studying the specific actions of hormone signaling pathways. Speci-
ficity is typically associated with the receptor and its cognate ligand. However, SRC-3 has distinguished itself 
by persistent association with cell growth. In the February 29 issue of Molecular Cell, Yi et al. demonstrate 
that estrogen-induced posttranslational modulation of SRC-3 by atypical PKC shields it from proteasomal 
degradation, facilitating increased estrogenic gene activity. This process may have important implications 
in different types of hormone-sensitive tumors, particularly breast cancer.Breast cancer is the most commonly diag-
nosed cancer among women; in 2008, 
some 182,460 new cases are expected, 
and from these, 40,480 deaths are esti-
mated (American Cancer Society, 2008). 
As with any complex disease, devel-
opment of new therapies depends on 
knowledge of the underlying source of the 
problem. The relationship of the estrogen 
receptor (ER), a member of the nuclear 
hormone receptor (NR) family, with breast 
cancer has been a focus of these stud-
ies. Since many breast tumors prolifer-
ate in response to the female sex steroid 
estrogen, current treatment includes 
various forms of endocrine therapy. The 
most commonly used form of treatment 
is tamoxifen, a selective ER modulator 
(SERM) that competitively inhibits estra-
diol binding to the ER. The predominance 
of studies on the actions of ER in breast 
cancer often overlooks the importance of 
nuclear receptor coactivators as a major 
determinate of ER transcriptional activity 
in breast cancer.
The nuclear receptor coactivator 
SRC-3 was simultaneously cloned by 
several groups in 1997 as a CBP-interact-
ing protein (p/CIP; Torchia et al., 1997), a 
nuclear receptor cofactor for activated 
retinoid and thyroid hormone recep-
tors (ACTR; Chen et al., 1997), and as it 
relates to this article amplified in breast 
cancer (AIB1; Anzick et al., 1997). Sub-
sequent studies have shown that SRC-3 
is an atypical histone acetyltransferase 
(HAT) (Chen et al., 1999) whose increased 
expression is associated with hormone-184 Cancer Cell 13, March 2008 ©2008 Elsesensitive tumors such as prostate and 
ovarian cancer in addition to hormone-
independent cancers such as pancreatic 
Figure 1. ER-Dependent Resistance of 
SRC-3 Degradation via aPKC Activity
Schematic pathway of how inhibition of SRC-3 pro-
teasomal degradation via aPKC-mediated phos-
phorylation in an ER-dependent manner leads to an 
increase in total cellular levels of SRC-3.vier Inc.and gastric cancers. It is a member of the 
p160 class of nuclear receptor coactiva-
tor proteins that associate with NRs in 
a ligand-dependent manner to promote 
their transcriptional activation of target 
genes. While nuclear receptor cofac-
tors like SRC-3 are generally thought 
to facilitate the actions of NR activity, 
growing evidence shows that relative 
cofactor concentration can propor-
tionately drive receptor function. Thus, 
it may not be surprising that cofactor 
overexpression might directly contrib-
ute to disease, pathology, and outcome. 
How might overexpression or excess 
protein be achieved? In the case of the 
nuclear receptor coactivator PGC-1a, 
its levels are dramatically induced from 
a “bottom-up” path involving enhanced 
transcription-translation producing more 
protein (Puigserver and Spiegelman, 
2003). In contrast, in the current article 
the authors describe a “top-down” con-
trol pathway in which posttranslational 
modifications of SRC-3 can shield it 
from the jaws of the proteasome, lead-
ing to increased protein accumulation 
and increased activity of downstream 
targets genes such as those controlling 
cell growth (Yi et al., 2008).
Phosphorylation can be a double-
edged sword, as previous work has 
shown that both p38 MAP kinase and 
GSK-3 can trigger selective degrada-
tion of SRC-3 through either the 26S or 
the REGγ-mediated proteasome (Wu et 
al., 2007). In the present study, Yi and 
colleagues show that alternative phos-
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by the atypical PKC (aPKC) prevents 
20S proteasomal degradation of SRC-3, 
negating the effects of p38 MAP kinase 
and GSK-3 activity. The net result of aPKC 
phosphorylation is the cellular accumula-
tion of the coactivator and enhanced ER-
dependent gene transcription. Interest-
ingly, other NRs such as the progesterone 
receptor do not exhibit a similar ability 
to trigger phosphorylation of SRC-3 by 
aPKC, highlighting the relevance of this 
mechanism to estrogen-dependent breast 
cancer cell growth. The authors show 
that the normal degradation of SRC-3 
involves an initial interaction with the C8 
alpha component of the 20S proteasome. 
However, when hyperphosphorylated by 
aPKC, SRC-3 undergoes a conformational 
change, exposing a negatively charged 
sequence that inhibits the interaction with 
C8 via electrostatic repulsion, effectively 
shielding it from the proteasome and 
resulting in a net increase in the cellular 
pool of this cofactor.
The relevance of this finding to breast 
cancer pathology is strengthened by the A cancer stem cell hierarchy has been 
suggested to exist for melanomas in 
which primitive self-renewing melanoma 
cells, capable of initiating tumorigen-
esis, give rise to rapidly proliferating, 
more differentiated, and tumorigeni-
cally exhausted cells that constitute the 
bulk tumor population. Stem-like cells 
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far-reaching implications, as new theobservation that SRC-3 phosphorylation 
by aPKC is promoted by hormone-acti-
vated ER. This leads to a proposal that 
estradiol binding to ER allows the recep-
tor to associate and stabilize the SRC-
3-aPKC dimer (Figure 1). The presump-
tive trimeric complex facilitates SRC-3 
phosphorylation, which in turn increases 
transcription of ER of target genes. Inter-
estingly, overexpression of aPKC has 
been observed in a number of cancers 
(Regala et al., 2005), which may pro-
vide an independent means to enhance 
SRC-3 pool size and ER transcription. 
Beyond NRs, SRC-3 has been shown to 
be a coactivator of other transcriptional 
networks, including activator protein-1 
(AP-1), nuclear factor-κB (NFκB), signal 
transducer and activator of transcription 
(STAT), and E2F1, all of which have been 
associated with cell growth and cancer 
(Liao et al., 2002). Thus, the work pre-
sented by Yi and colleagues provides us 
with a new model of how posttranslation 
modifications of a NR coactivator may 
promote cancer while offering a new ther-
apeutic target to exploit in its treatment.Cancer C
have been propagated from both cul-
tured melanoma cells and fresh clinical 
specimens as nonadherent spheres in 
stem cell-supportive media, similar to 
mammo- and neurospheres, that could 
self-renew, differentiate into various mes-
enchymal lineages, and initiate tumors in 
xenotransplantation models with small 
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cell number (Fang et al., 2005). Further-
more, stem cell properties, including 
side population, and stem cell makers, 
including ABCG2, CD133, and nestin, 
have been identified in melanomas (Dou 
et al., 2007; Grichnik et al., 2006; Klein et 
al., 2007; Monzani et al., 2007). Despite 
this suggestive evidence, in depth in 
itiating Cells
a. Stem-like cells have been propa-
tem cell markers, including ABCG2 
tive markers for the purification and 
cently, Schatton et al. provided solid 
BCB5 marks primitive cells capable 
tion of melanoma-initiating cells has 
d that specifically target these cells.
